Current Report Filing (8-k)
May 12 2022 - 09:00AM
Edgar (US Regulatory)
0001535955 false 0001535955 2022-05-12
2022-05-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date
of Report (Date of Earliest Event Reported):
May 12, 2022

LIPOCINE INC.
(Exact
name of registrant as specified in its charter)
Commission
File No.
001-36357
Delaware |
|
99-0370688 |
(State
or other jurisdiction
of
incorporation)
|
|
(IRS
Employer
Identification
Number)
|
675 Arapeen Drive,
Suite 202
Salt Lake City,
Utah
84108
(Address
of principal executive offices) (Zip Code)
Registrant’s
telephone number, including area code:
(801)
994-7383
Former
name or former address, if changed since last report: Not
Applicable
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the
Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common Stock, par value $0.0001 per share |
|
LPCN |
|
The NASDAQ Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (17 CFR §
230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17
CFR § 240.12b-2).
Emerging
growth company
☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item
8.01 Other Events
On
May 12, 2022, the Company issued a press release announcing
positive LPCN 1144 NASH Open Label Extension study results. The
press release is filed as Exhibit 99.1 and is incorporated herein
by reference.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
The
following exhibits are filed with this report:
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
|
LIPOCINE
INC. |
|
|
|
|
|
Date: |
May
12, 2022 |
|
By: |
/s/
Mahesh V. Patel |
|
|
|
|
Mahesh
V. Patel |
|
|
|
|
President
and Chief Executive Officer |
Lipocine (NASDAQ:LPCN)
Historical Stock Chart
From Jul 2022 to Aug 2022
Lipocine (NASDAQ:LPCN)
Historical Stock Chart
From Aug 2021 to Aug 2022